Etanercept biosimilar - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Drug Profile

Etanercept biosimilar - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Alternative Names: Recombinant human TNF receptor p75-Fc fusion protein

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  • Class Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 05 Sep 2017 No recent reports on development identified - Preregistration for Rheumatoid arthritis in China (Parenteral) (Shanghai Fudan Bio-Pharmaceutical website, September 2017)
  • 15 Mar 2016 Biomarkers information updated
  • 12 May 2015 Preregistration for Rheumatoid arthritis in China (Parenteral) before May 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top